GORTEC Announces New Trial Success for Head and Neck Cancer Treatment
GORTEC, known as Head and Neck Radiation Oncology Group, today announced that the randomized Phase 3 NIVOPOSTOP GORTEC ...
The American Journal of Managed Care4d
FDA Approves First Subcutaneous Nivolumab Injection in Most Solid Tumors
FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.
Pharmaceutical Technology1d
Nivolumab biosimilar by Amgen for Metastatic Melanoma: Likelihood of Approval
Nivolumab biosimilar is under clinical development by Amgen and currently in Phase III for Metastatic Melanoma.
Targeted Oncology10d
FDA Approves Subcutaneous Nivolumab Across Existing Solid Tumor Indications
On December 27, 2024, subcutaneous nivolumab (Opdivo Qvantig) was approved by the FDA in all previously approved adult solid ...
Monthly Prescribing Reference4d
FDA Approves Opdivo Qvantig, a Subcutaneous Formulation of Nivolumab
The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.
FDA approves subcutaneous opdivo qvantig for most solid tumor indications
The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...
I-Mab pauses CD73 antibody development in pipeline reshuffle
As part of the reshuffle, I-Mab will prioritise the advancement of givastomig, a CLDN18.2 x 4-1BB bispecific antibody, ...
Arbutus: Positive Imdusiran Data Leads To Phase 2B Development
Learn about Arbutus's promising Hepatitis B treatments, strong financial position, and projections for the global market.
Pharmaceutical Technology7d
Nivolumab by Bristol-Myers Squibb for Osteosarcoma: Likelihood of Approval
Nivolumab is under clinical development by Bristol-Myers Squibb and currently in Phase II for Osteosarcoma. According to GlobalData, Phase II drugs for Osteosarcoma have a 13% phase transition success ...
Medical Xpress29d
Study finds increased survival with nivolumab plus ipilimumab vs. chemo for metastatic colorectal cancer
In this prespecified interim analysis, nivolumab plus ipilimumab was compared to chemotherapy. Overall, 303 patients who had not previously received systemic treatment were randomly assigned to ...